Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.
July 11, 2019: Seroconversion while on long-acting contraceptives; cardiovascular risk in people with HIV; suboptimal testing in high-prevalence U.S. areas; E/C/F/TAF may be suitable for PEP.
May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
FDA recently approved changes to the Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) fixed-dose combination tablet product labeling.
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a complete treatment in one pill that comes in the form of green capsule-shaped tablets. The dose of Genvoya used by adults with HIV is one tablet once daily with food.
The first TAF-containing medicine, Genvoya, was licensed by the U.S. Food and Drug Administration (FDA) in November 2015 and will likely be licensed by Health Canada late in 2015.
With the FDA approval of Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide), we now have a fifth one-pill-a-day treatment for HIV. On the surface, the only thing new here is the tenofovir alafenamide (TAF) component. So what does T...